NASDAQ: INABIn8bio Inc Stock
$0.16+0.00 (+0%)
Updated Apr 17, 2025
INAB Price
$0.16
Fair Value Price
$0.11
Market Cap
$13.08M
52 Week Low
$0.13
52 Week High
$1.74
P/E
-0.28x
P/B
0.9x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$30.44M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.45
Operating Cash Flow
-$24M
Beta
0.95
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
INAB Overview
IN8bio Incorporated is a biotech company developing gamma-delta T cell therapies for the treatment of cancers. Its pipeline includes INB-200, a genetically modified autologous gamma-delta T cell candidate in Phase I clinical trials for the treatment of glioblastoma and solid tumors, and INB-100, an allogeneic product candidate, in Phase I clinical trials to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. IN8bio was incorporated in 2016 and is headquartered in New York, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine INAB's potential to beat the market
- INAB doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
INAB
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important INAB news, forecast changes, insider trades & much more!
INAB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how INAB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INAB ($0.16) is overvalued by 41.56% relative to our estimate of its Fair Value price of $0.11 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
INAB ($0.16) is not significantly undervalued (41.56%) relative to our estimate of its Fair Value price of $0.11 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
INAB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more INAB due diligence checks available for Premium users.
Valuation
INAB fair value
Fair Value of INAB stock based on Discounted Cash Flow (DCF)
Price
$0.16
Fair Value
$0.11
Overvalued by
40.68%
INAB ($0.16) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
INAB ($0.16) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
INAB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
INAB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.28x
Industry
-177.72x
Market
27.98x
INAB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.9x
Industry
4.05x
INAB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INAB's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.2M
Profit Margin
0%
INAB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$20.9M
Liabilities
$6.5M
Debt to equity
0.45
INAB's short-term assets ($12.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INAB's short-term assets ($12.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INAB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
INAB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.0M
Investing
-$33.0k
Financing
$11.2M
INAB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
INAB vs Biotech Stocks
In8bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.